clinical trial · NCT07281768
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·not yet recruiting·n = 66
Colorectal CancerOxaliplatinCapecitabineCemiplimabFianlimabREGN7075
brief summary
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-positive, T3 node-negative, T3 node-positive).
started
Jul 1, 2026
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
May 6, 2026
official title
Combining Capecitabine/Oxaliplatin Chemotherapy With Cemiplimab Alone or in Combination With Fianlimab or REGN7075 for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol